Beam Therapeutics(BEAM.US)

Last Updated 19:00:00 ET
longbridge loading

Beam Therapeutics Eyes Sickle Cell BLA as Alpha-1 Gene-Editing Program Advances

Market Beat·
US
BEAM
+2.54%
Market Beat·
US
BEAM
+2.54%

A Look At Beam Therapeutics (BEAM) Valuation As New BEACON Trial Data And Partnerships Draw Attention

Simplywall·
US
BEAM
+2.54%
US
BIB
+4.03%
US
PBE
+1.37%
Simplywall·
US
BEAM
+2.54%
US
BIB
+4.03%
US
PBE
+1.37%

Beam Therapeutics: Buy Rating Reaffirmed as Clinical Momentum Builds and $68 Price Target Remains Unchanged

Tip Ranks·
US
BEAM
+2.54%
US
FBT
+1.76%
US
IBB
+1.85%
Tip Ranks·
US
BEAM
+2.54%
US
FBT
+1.76%
US
IBB
+1.85%

Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1 | BEAM Stock News

StockTitan·
US
BEAM
+2.54%
US
FBT
+1.76%
US
XBI
+3.45%
StockTitan·
US
BEAM
+2.54%
US
FBT
+1.76%
US
XBI
+3.45%

IBA introduces AdaPTinsight XR, the next generation of CBCT imaging for image-guided proton therapy

Unusual Whales·
US
BMR
+1.37%
US
BEEM
+2.50%
US
BEAM
+2.54%
Unusual Whales·
US
BMR
+1.37%
US
BEEM
+2.50%
US
BEAM
+2.54%

Will Beam Therapeutics' (BEAM) Revenue Surge, Pipeline Updates and Added Liquidity Change Its Narrative?

Simplywall·
US
BEAM
+2.54%
US
SBIO
+3.58%
US
BBH
+0.68%
Simplywall·
US
BEAM
+2.54%
US
SBIO
+3.58%
US
BBH
+0.68%

Beam Therapeutics | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 31.74 M

Earnings Watch·
US
BEAM
+2.54%
Earnings Watch·
US
BEAM
+2.54%

A Look At Beam Therapeutics (BEAM) Valuation After TIME Recognition And BEACON Trial Progress

Simplywall·
US
BEAM
+2.54%
US
FBT
+1.76%
US
PBE
+1.37%
Simplywall·
US
BEAM
+2.54%
US
FBT
+1.76%
US
PBE
+1.37%
© 2026 Longbridge｜Disclaimer